STOCK TITAN

[6-K] COMPUGEN LTD Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Compugen Ltd. (CGEN) filed a Form 6-K noting it issued a press release on October 13, 2025, which is furnished as Exhibit 99.1. With the exception of the third, fourth, and fifth paragraphs of the press release, the information incorporated by reference in this report is also incorporated into the Company’s Registration Statement on Form F-3 (File No. 333-270985).

The report was signed by Eran Ben Dor, General Counsel, on October 14, 2025.

Compugen Ltd. (CGEN) ha presentato un modulo 6-K indicando che ha emesso un comunicato stampa il 13 ottobre 2025, che è fornito come Allegato 99.1. Con l'eccezione del terzo, quarto e quinto paragrafo del comunicato stampa, le informazioni incorporate per riferimento in questo rapporto sono anch'esse incorporate nella Registrazione della Società sul modulo F-3 (Numero di file 333-270985).

Il rapporto è stato firmato da Eran Ben Dor, Avvocato generale, il 14 ottobre 2025.

Compugen Ltd. (CGEN) presentó un Formulario 6-K señalando que emitió un comunicado de prensa el 13 de octubre de 2025, el cual se adjunta como el Anexo 99.1. Con excepción de los párrafos tercero, cuarto y quinto del comunicado de prensa, la información incorporada por referencia en este informe también se incorpora al Registro de la Compañía en el Formulario F-3 (Número de expediente 333-270985).

El informe fue firmado por Eran Ben Dor, Consejero General, el 14 de octubre de 2025.

컴퓨젠 주식회사(CGEN)은 Form 6-K를 제출했습니다 2025년 10월 13일 보도자료를 발행했다는 내용을 명시했고, 이는 부록 99.1로 제공합니다. 보도자료의 3, 4, 5단락을 제외한 이 보고서에 참조로 포함된 정보는 회사의 Form F-3 등록 신청서(파일 번호 333-270985)에도 포함됩니다.

보고서는 2025년 10월 14일에 이란 벤 도르(Eran Ben Dor), 법무 고문이 서명했습니다.

Compugen Ltd. (CGEN) a déposé un Form 6-K indiquant qu'il a publié un communiqué de presse le 13 octobre 2025, qui est Joint comme Exposé 99.1. À l'exception des troisième, quatrième et cinquième paragraphes du communiqué de presse, les informations incorporées par référence dans ce rapport sont également incorporées dans le Registre de la Société sur le Formulaire F-3 (numéro de fichier 333-270985).

Le rapport a été signé par Eran Ben Dor, Conseiller juridique général, le 14 octobre 2025.

Compugen Ltd. (CGEN) hat ein Form 6-K eingereicht und mitgeteilt, dass am 13. Oktober 2025 eine Pressemitteilung veröffentlicht wurde, die als Anhang 99.1 beigefügt ist. Mit Ausnahme des dritten, vierten und fünften Absatzes der Pressemitteilung sind die im Bericht durch Verweis aufgenommenen Informationen auch in der Registrierung der Gesellschaft auf dem Formular F-3 (Datei Nr. 333-270985) enthalten.

Der Bericht wurde am 14. Oktober 2025 von Eran Ben Dor, General Counsel, unterzeichnet.

Compugen Ltd. (CGEN) قد تقديمت نموذج 6-K مشيرة إلى أنها أصدرت بياناً صحفياً في 13 أكتوبر 2025، والذي يُعرض كمرفق 99.1. باستثناء الفقرات الثالثة والرابعة والخامسة من البيان الصحفي، فإن المعلومات المدرجة بالمرجع في هذا التقرير مدرجة أيضاً في بيان الشركة على النموذج F-3 (رقم الملف 333-270985).

تم توقيع التقرير من قبل إيران بن دور، المستشار العام، في 14 أكتوبر 2025.

Compugen Ltd. (CGEN) 提交了 Form 6-K,指出它在 2025 年 10 月 13 日发布了一份新闻稿,作为附件 99.1 提供。除了新闻稿的第三、第四和第五段之外,本文所引用的信息也已纳入公司在 Form F-3(档案编号 333-270985)上的注册声明。

该报告由 Eran Ben Dor,首席法务官,于 2025 年 10 月 14 日签署。

Positive
  • None.
Negative
  • None.

Compugen Ltd. (CGEN) ha presentato un modulo 6-K indicando che ha emesso un comunicato stampa il 13 ottobre 2025, che è fornito come Allegato 99.1. Con l'eccezione del terzo, quarto e quinto paragrafo del comunicato stampa, le informazioni incorporate per riferimento in questo rapporto sono anch'esse incorporate nella Registrazione della Società sul modulo F-3 (Numero di file 333-270985).

Il rapporto è stato firmato da Eran Ben Dor, Avvocato generale, il 14 ottobre 2025.

Compugen Ltd. (CGEN) presentó un Formulario 6-K señalando que emitió un comunicado de prensa el 13 de octubre de 2025, el cual se adjunta como el Anexo 99.1. Con excepción de los párrafos tercero, cuarto y quinto del comunicado de prensa, la información incorporada por referencia en este informe también se incorpora al Registro de la Compañía en el Formulario F-3 (Número de expediente 333-270985).

El informe fue firmado por Eran Ben Dor, Consejero General, el 14 de octubre de 2025.

컴퓨젠 주식회사(CGEN)은 Form 6-K를 제출했습니다 2025년 10월 13일 보도자료를 발행했다는 내용을 명시했고, 이는 부록 99.1로 제공합니다. 보도자료의 3, 4, 5단락을 제외한 이 보고서에 참조로 포함된 정보는 회사의 Form F-3 등록 신청서(파일 번호 333-270985)에도 포함됩니다.

보고서는 2025년 10월 14일에 이란 벤 도르(Eran Ben Dor), 법무 고문이 서명했습니다.

Compugen Ltd. (CGEN) a déposé un Form 6-K indiquant qu'il a publié un communiqué de presse le 13 octobre 2025, qui est Joint comme Exposé 99.1. À l'exception des troisième, quatrième et cinquième paragraphes du communiqué de presse, les informations incorporées par référence dans ce rapport sont également incorporées dans le Registre de la Société sur le Formulaire F-3 (numéro de fichier 333-270985).

Le rapport a été signé par Eran Ben Dor, Conseiller juridique général, le 14 octobre 2025.

Compugen Ltd. (CGEN) hat ein Form 6-K eingereicht und mitgeteilt, dass am 13. Oktober 2025 eine Pressemitteilung veröffentlicht wurde, die als Anhang 99.1 beigefügt ist. Mit Ausnahme des dritten, vierten und fünften Absatzes der Pressemitteilung sind die im Bericht durch Verweis aufgenommenen Informationen auch in der Registrierung der Gesellschaft auf dem Formular F-3 (Datei Nr. 333-270985) enthalten.

Der Bericht wurde am 14. Oktober 2025 von Eran Ben Dor, General Counsel, unterzeichnet.



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025
Commission File Number 000-30902

COMPUGEN LTD.
(Translation of registrant’s name into English)

26 Harokmim Street
Holon 5885849, Israel
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒  Form 40-F ☐



Compugen Ltd.

On October 13, 2025, Compugen Ltd. (the “Company”) issued a press release (the “Press Release”), a copy of which is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated by reference herein.

With the exception of the third, fourth, and fifth paragraphs of the Press Release, the information incorporated by reference in this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3, File No. 333-270985.

Exhibit
Number

Description of Exhibit

99.1
Press Release dated October 13, 2025 – “Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025”



 
Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
COMPUGEN LTD.
 
Date: October 14, 2025
By: 
/s/ Eran Ben Dor          
 
 
 
Eran Ben Dor
General Counsel
 


FAQ

What did Compugen (CGEN) file?

Compugen filed a Form 6-K reporting it issued a press release on October 13, 2025.

How is the press release included in the filing?

The press release is furnished as Exhibit 99.1 to the Form 6-K.

Is the 6-K incorporated into Compugen’s F-3?

Yes. With the exception of the third, fourth, and fifth paragraphs of the press release, the information incorporated by reference here is also incorporated into the Form F-3.

What is the Form F-3 file number for Compugen?

The Registration Statement on Form F-3 has file number 333-270985.

When was the report signed and by whom?

It was signed by Eran Ben Dor, General Counsel, on October 14, 2025.

What is Compugen’s principal executive office address?

The address is 26 Harokmim Street, Holon 5885849, Israel.
Compugen

NASDAQ:CGEN

CGEN Rankings

CGEN Latest News

CGEN Latest SEC Filings

CGEN Stock Data

182.39M
91.64M
2.03%
16.56%
1.01%
Biotechnology
Healthcare
Link
Israel
Holon